| LncRNA Information | ||||||
|---|---|---|---|---|---|---|
| ID | EL0011 | Name | 9530018H14Rik | Aliases | lncRNA-HIT | |
| Species | Mus musculus | Chromosome | 6 | Start site | N/A | |
| End site | N/A | Chain | N/A | Exon NO. | N/A | |
| Assembly | N/A | Class | N/A | NCBI accession | AK020562 | |
| Ensembl | N/A | Sequence | ||||
| Disease | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source | ||
| breast cancer | qPCR, Luciferase reporter assay etc. | breast cancer tissue, cell lines(NMuMG, 4T1) | up-regulated | expression | The level of expression of lncRNA-HIT in normal breast tissue was low and gradually increased to invasive carcinoma suggesting lncRNA-HIT may play a role in tumor progression in humans. These data further support the findings demonstrating the involvement of lncRNA-HIT in EMT and invasion as observed in NMuMG and 4T1 cells, and suggest that conserved human lncRNA-HIT could play a pivotal role in breast cancer metastasis. | 25605728 | Lnc2Cancer | ||
| Function (not disease relevant) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Methods | Sample/condition | Expression pattern | Dysfunction type | Description | PMID | Source | |||
| ChIRP-seq, siRNA-mediated reductions | E 11 mouse embryos | up-regulated | interaction | Mechanistically the LncRNA-HIT siRNA treatments impacted pro-chondrogenic gene expression by reducing H3K27ac or p100 activity, confirming that LncRNA-HIT is essential for chondrogenic differentiation in the limb mesenchyme. | 26633036 | ||||
| Interaction | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Interaction target | Level of interaction | Type of interaction | Description | PMID | Source | ||||
| p100 and CBP | RNA-Protein | binding | In the limb mesenchyme, LncRNA-HIT was found to be retained in the nucleus, forming a complex with p100 and CBP. | 26633036 | |||||